- Home
- ABLV vs RNXT Comparison
ABLV vs RNXT Comparison
Compare ABLV & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABLV
- RNXT
- Stock Information
- Founded
- ABLV 2015
- RNXT 2012
- Country
- ABLV China
- RNXT United States
- Employees
- ABLV N/A
- RNXT N/A
- Industry
- ABLV
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- ABLV
- RNXT Health Care
- Exchange
- ABLV Nasdaq
- RNXT Nasdaq
- Market Cap
- ABLV 51.4M
- RNXT 43.2M
- IPO Year
- ABLV N/A
- RNXT 2021
- Fundamental
- Price
- ABLV N/A
- RNXT $1.21
- Analyst Decision
- ABLV
- RNXT Strong Buy
- Analyst Count
- ABLV 0
- RNXT 2
- Target Price
- ABLV N/A
- RNXT $7.50
- AVG Volume (30 Days)
- ABLV 12.8K
- RNXT 851.9K
- Earning Date
- ABLV 04-23-2025
- RNXT 11-12-2025
- Dividend Yield
- ABLV N/A
- RNXT N/A
- EPS Growth
- ABLV N/A
- RNXT N/A
- EPS
- ABLV 0.05
- RNXT N/A
- Revenue
- ABLV $114,319,869.00
- RNXT $662,000.00
- Revenue This Year
- ABLV N/A
- RNXT $2,895.35
- Revenue Next Year
- ABLV N/A
- RNXT $313.04
- P/E Ratio
- ABLV $20.65
- RNXT N/A
- Revenue Growth
- ABLV N/A
- RNXT N/A
- 52 Week Low
- ABLV $0.55
- RNXT $0.75
- 52 Week High
- ABLV $1.77
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- ABLV N/A
- RNXT 52.27
- Support Level
- ABLV N/A
- RNXT $1.24
- Resistance Level
- ABLV N/A
- RNXT $1.42
- Average True Range (ATR)
- ABLV 0.00
- RNXT 0.10
- MACD
- ABLV 0.00
- RNXT -0.00
- Stochastic Oscillator
- ABLV 0.00
- RNXT 33.00
About ABLV Able View Global Inc.
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.